| Followers | 0 |
| Posts | 2177 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2018 |
Tuesday, August 24, 2021 1:10:41 PM
Nader Rebuked Again! CYDY Bankruptcy Coming!
While not as stunning as the FDA letter which forced Nader to recant some of his worst lies. The much less dramatized rebuke of Nader by Brazil's health agency is no less stunning.
Nader "The Chipped Tooth Liar" Pourhassan, a felon with multiple convictions and CEO of floundering CYDY was caught in yet another lie. Nader along with lap dog Scott "Sports Medicine" Kelly trumpeted the lie that CYDY would be running full clinical trials in Brazil. However Anvisa, Brazil's Health Agency, quickly slammed the brakes on the Pourhassan/Kelly deception road show:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165595857
Instead of full clinical trials as Nader led investors and the world to believe, it is actually just a health and safety evaluation of Leronlimab. Leronlimab was once an HIV drug that received a refusal to file from the FDA due to irregularities in it's application. It was then dusted off and trotted out as COVID drug; where it since been a clinical failure in every trial for COVID.
Despite being under a criminal investigation by the DOJ, Nader went ahead and made his claims only to be shutdown by Anvisa's clarifying statement. The implications of course are dire for both Nader and the company.
As already mentioned Nader faces a criminal probe from the DOJ likely regarding securities fraud. But he is also facing a challenge from an upcoming proxy battle he has illegally tried to block. Should the proxy battle occur and not go in his favor, he would be quickly ousted.
But the much greater danger is to the company and shareholders. CYDY is currently burning cash at a rate that will see it likely take drastic measures sometime in October. But with revelations that this study only deals with health and safety, it means the time line for actual clinical results will have to wait well into 2022.
Again actual clinical results for efficacy in Brazil won't be available until well into 2022. At which time multiple vaccines and other COVID therapy drugs will likely have received EUAs or BLAs raising the question of why the company is dumping money into this project. Of course there are answers.
If the company was financially sound and generating revenue, the argument would be you follow up every lead in the pursuit of growing your business. But CYDY isn't generating revenue.
As of today not one single vial has been sold and the phantom Philippines deal is still a bitter pill for investors to swallow.
No sadly the real reasons appear to be the same old stock pumping schemes Nader "The Chipped Tooth Liar" Pourhassan appears to enjoy engaging in. None of his actions as CEO have been sound and lack rhyme or reason. This only adds to the appearance and likelihood that deception is apart of this CEO's toolkit.
While some remain wildly optimistic claiming that there is a light at the end of this tunnel. More astute commentators, investors and market makers see CYDY as a mineshaft were investors plummet to the bottom with no hope of seeing daylight again.
Hats off to everyone that got out and made money, this stock is officially a scam until proven otherwise!
While not as stunning as the FDA letter which forced Nader to recant some of his worst lies. The much less dramatized rebuke of Nader by Brazil's health agency is no less stunning.
Nader "The Chipped Tooth Liar" Pourhassan, a felon with multiple convictions and CEO of floundering CYDY was caught in yet another lie. Nader along with lap dog Scott "Sports Medicine" Kelly trumpeted the lie that CYDY would be running full clinical trials in Brazil. However Anvisa, Brazil's Health Agency, quickly slammed the brakes on the Pourhassan/Kelly deception road show:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165595857
Instead of full clinical trials as Nader led investors and the world to believe, it is actually just a health and safety evaluation of Leronlimab. Leronlimab was once an HIV drug that received a refusal to file from the FDA due to irregularities in it's application. It was then dusted off and trotted out as COVID drug; where it since been a clinical failure in every trial for COVID.
Despite being under a criminal investigation by the DOJ, Nader went ahead and made his claims only to be shutdown by Anvisa's clarifying statement. The implications of course are dire for both Nader and the company.
As already mentioned Nader faces a criminal probe from the DOJ likely regarding securities fraud. But he is also facing a challenge from an upcoming proxy battle he has illegally tried to block. Should the proxy battle occur and not go in his favor, he would be quickly ousted.
But the much greater danger is to the company and shareholders. CYDY is currently burning cash at a rate that will see it likely take drastic measures sometime in October. But with revelations that this study only deals with health and safety, it means the time line for actual clinical results will have to wait well into 2022.
Again actual clinical results for efficacy in Brazil won't be available until well into 2022. At which time multiple vaccines and other COVID therapy drugs will likely have received EUAs or BLAs raising the question of why the company is dumping money into this project. Of course there are answers.
If the company was financially sound and generating revenue, the argument would be you follow up every lead in the pursuit of growing your business. But CYDY isn't generating revenue.
As of today not one single vial has been sold and the phantom Philippines deal is still a bitter pill for investors to swallow.
No sadly the real reasons appear to be the same old stock pumping schemes Nader "The Chipped Tooth Liar" Pourhassan appears to enjoy engaging in. None of his actions as CEO have been sound and lack rhyme or reason. This only adds to the appearance and likelihood that deception is apart of this CEO's toolkit.
While some remain wildly optimistic claiming that there is a light at the end of this tunnel. More astute commentators, investors and market makers see CYDY as a mineshaft were investors plummet to the bottom with no hope of seeing daylight again.
Hats off to everyone that got out and made money, this stock is officially a scam until proven otherwise!
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
